Skip to content
  • Sunday, 13 September 2026
  • 2:09 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Gilead Sciences Pledges Over 400,000 Doses of AmBisome to Combat Visceral Leishmaniasis, Extending Vital Global Health Partnership
Pharmaceutical R&D

Gilead Sciences Pledges Over 400,000 Doses of AmBisome to Combat Visceral Leishmaniasis, Extending Vital Global Health Partnership

Teuku Ryan May 21, 2026 0

Gilead Sciences has announced a significant commitment to global health, pledging over 400,000 doses of its vital antifungal medication, AmBisome…

Read More
Pharmaceutical R&D

Eli Lilly Acquires Engage Biologics for Up to $202 Million, Bolstering Its Genetic Medicine Pipeline with Innovative Non-Viral DNA Delivery Technology

Teuku Ryan May 21, 2026 0

Pharmaceutical giant Eli Lilly and Company has announced its agreement to acquire Engage Biologics, a California-based biotechnology firm, for a…

Read More
Pharmaceutical R&D

Takeda Ordered to Pay $885 Million in Landmark "Pay-for-Delay" Drug Case, Faces Potential $2.5 Billion Liability

Teuku Ryan May 21, 2026 0

In a groundbreaking verdict that could reshape pharmaceutical antitrust litigation, a U.S. jury has found Japanese pharmaceutical giant Takeda liable…

Read More
Pharmaceutical R&D

China Ascends to Global Clinical Trial Leadership as Immunology and Metabolic Diseases Emerge as Key Growth Areas

Teuku Ryan May 21, 2026 0

As the global pharmaceutical industry navigates the dynamic landscape of clinical research, China has firmly established its dominance in trial…

Read More
Pharmaceutical R&D

Global Healthcare Giants Unite: GHO Capital and CBC Group Forge Largest Dedicated Investment Manager with $21 Billion AUM

Teuku Ryan May 20, 2026 0

Two prominent forces in specialized healthcare investment, Global Healthcare Opportunities (GHO) and CBC Group, have announced a groundbreaking merger to…

Read More
Pharmaceutical R&D

QIAGEN Digital Insights Partners with NVIDIA to Revolutionize AI-Driven Drug Discovery

Teuku Ryan May 20, 2026 0

The integration of NVIDIA’s accelerated computing and BioNeMo platform with QIAGEN Digital Insights’ bioinformatics capabilities is poised to usher in…

Read More
Pharmaceutical R&D

The Evolving Landscape of Ovarian Cancer Research: Navigating Complexity and Embracing Global Strategies

Teuku Ryan May 20, 2026 0

The field of ovarian cancer research is undergoing a profound transformation, driven by significant advancements in personalized medicine and innovative…

Read More
Pharmaceutical R&D

Regeneron Pharmaceuticals and Parabilis Medicines Forge Landmark $2.32 Billion Collaboration to Pioneer a New Era of Intracellular Therapies

Teuku Ryan May 20, 2026 0

Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…

Read More
Pharmaceutical R&D

UK Secures Favipiravir Supply from Japan to Bolster Hantavirus Preparedness

Teuku Ryan May 19, 2026 0

The United Kingdom has received a crucial supply of the antiviral medication favipiravir from the Japanese government, a strategic move…

Read More
Pharmaceutical R&D

VERTANICAL’s Investigational Non-Opioid Chronic Low Back Pain Treatment VER-01 Receives FDA Breakthrough Therapy Designation

Teuku Ryan May 19, 2026 0

VERTANICAL has announced a significant milestone in its development of VER-01, an investigational non-opioid therapeutic candidate for chronic low back…

Read More

Posts pagination

1 … 13 14 15 … 33
Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology PipelineScience News: A Century of Illuminating the Frontiers of KnowledgeThe World Health Organization Targets Urgent Antibiotic Development to Combat Evolving Drug ResistanceInternational Research Team Achieves Breakthrough in Long Distance Quantum Key Distribution Using Semiconductor Quantum Dots and Time Bin Encoding
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
Breakthrough Combination Therapy Offers New Hope for Acute Myelogenous Leukemia Patients by Targeting Cellular Differentiation BlocksBreakthrough Methodological Advances in Proteomics Unlock New Frontiers in Protein Dynamics, Sequencing, and SynthesisAbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.Persistent financial hardship may speed up age-related cognitive decline, according to new research led by University College London (UCL).
YOU MAY HAVE MISSED
Stem Cell & Regenerative Medicine
Breakthrough Combination Therapy Offers New Hope for Acute Myelogenous Leukemia Patients by Targeting Cellular Differentiation Blocks
Dwi Wanna Sep 13, 2026
Biotech & Genetic Research
Breakthrough Methodological Advances in Proteomics Unlock New Frontiers in Protein Dynamics, Sequencing, and Synthesis
Jia Lissa Sep 13, 2026
Laboratory Automation & Robotics
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
Lana Keisha Sep 13, 2026
Neuroscience & Brain Research
Persistent financial hardship may speed up age-related cognitive decline, according to new research led by University College London (UCL).
Rifan Muazin Sep 13, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ